Earnings Releases·Nov 4, 2026, 4:18 PM ET

Nuvation Bio — Third Quarter 2026 Earnings Summary

Total revenue reached $45.0 million in Q3 2026, up from $13.1 million in the prior year period, driven by $27.5 million in net product revenue and $17.5 million in collaboration and license agreements; net loss narrowed to $41.9 million ($0.12 per share) from $55.8 million ($0.16 per share) year-over-year.
IBTROZI established market leadership in advanced ROS1+ NSCLC with consistent new patient starts despite a 15% decline in the broader TKI market, supported by a September 2026 FDA label update and inclusion in China's National Reimbursement Drug List.
Safusidenib received FDA Fast Track Designation in August 2026 for IDH1-mutant glioma, with pivotal Phase 3 studies initiated in the U.S. and expanded internationally, alongside plans to advance development across multiple subpopulations.
The company holds $663.4 million in cash, cash equivalents, and marketable securities as of September 30, 2026, following the July 2026 exercise of the greenshoe option on convertible notes which increased aggregate principal to $287.5 million.
Future outlook includes updates on the drug-drug conjugate (DDC) platform by year-end 2026 and an estimated 2030 primary completion date for the TRUST-IV Phase 3 study in adjuvant treatment of early-stage ROS1+ NSCLC.